<DOC>
	<DOCNO>NCT00998283</DOCNO>
	<brief_summary>- Study Design - Randomized , Double-blind , Placebo-controlled , escalate single-dose design . - Five ascend dose cohort . - In cohort , subject randomize receive single dose HM10460A placebo ( negative control ) - Objectives - The primary objective study assess safety tolerability single escalate subcutaneous dos HM10460A healthy adult Korean Subjects</brief_summary>
	<brief_title>Assess Safety , Tolerability , Pharmacokinetic ( PK ) Characteristics HM10460A ( HNK460 ) Healthy Adult Korean Subjects</brief_title>
	<detailed_description>The secondary objective study follow : - ass pharmacokinetics ( PK ) single subcutaneous dose HM10460A . - ass relationship serum concentration HM10460A absolute neutrophil count ( ANC ) . - ass relationship serum concentration HM10460A CD34+ cell count blood . - ass immunogenicity ( HM10460A , native G-CSF antibody , neutralize antibody ) single subcutaneous dose HM10460A .</detailed_description>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Healthy adult Korean male and/or female , 20 45 year age ( inclusive ) . BMI 18 27kg/m2 . Medically healthy clinically significant screen result . The following result laboratory test Absolute neutrophil count ( ANC ) : 2000 ~ 7500/mm3 Nonsmokers subject smoke less 10 cigarettes/day After confirm menstrual period , female childbearing potential must either sexually inactive ( abstinent ) 14 day prior screen agree remain throughout study , use highly effective method birth control , follow example : intrauterine device place least 3 month prior Day 1 ; stable hormonal contraceptive least 3 month prior Day 1 completion study ; surgical sterilization ( vasectomy ) partner least 6 month prior Day 1 . Females nonchildbearing potential must undergo one follow sterilization procedure least 6 month prior Day 1 : bilateral tubal ligation ; hysterectomy ; hysterectomy unilateral bilateral oophorectomy ; bilateral oophorectomy . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . Positive urine drug/alcohol test screen checkin . Positive test HIV , HBsAg , HCV antibody . Active infection Positive test palpable spleen screen checkin . The following result laboratory test : WBC &gt; 10.0 x 10^3/mm3 Hb &lt; 13g/dL Platelet &lt; 150 x 10^3/mm3 AST/ALT &gt; 50 IU/L History presence alcoholism drug abuse within 2 year prior Day 1 . History GCSFrelated product use ( i.e. , pegfilgrastim , filgrastim ) . History anaphylactic reaction medicine environmental exposure . Use prescription medication ( exception hormonal contraceptive female ) receipt blood product within 14 day prior Day 1 . Use overthecounter medication , include herbal product , within 7 day prior Day 1 . Up 2 gram per day acetaminophen allow discretion Investigator . Blood donation significant blood loss within 56 day prior Day 1 . Plasma donation within 7 day prior Day 1 . Participation another clinical trial ( receipt last investigational medication ) within 30 day prior Day 1 . Females pregnant lactating . Subjects unlikely comply protocol requirement , instruction study related restriction ; e.g. , uncooperative attitude , inability return followup visit improbability complete clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>